⏳ Fetching live dividend data...
Home › Calculator › ATNX Dividend Calculator 2026
Athenex, Inc. · NASDAQ
Price: $0.20 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ATNX → $316259.03M in 10 years · $16,024,460,100.37/month
Athenex, Inc. is a biopharmaceutical company primarily dedicated to the discovery, advancement, and commercialization of therapeutic agents for oncological conditions. Its operations are structured across three distinct platforms: an Oncology Innovation Platform, a Global Supply Chain Platform, and a Commercial Platform. Among its leading product candidates is the Orascovery series, featuring oral paclitaxel combined with encequidar – an innovative oral formulation. This product is currently undergoing a Phase III clinical trial for metastatic breast cancer, alongside earlier-stage studies for cutaneous angiosarcoma, advanced gastric cancer, and various other advanced solid malignancies. Additionally, Athenex offers Src Kinase inhibitors, exemplified by Tirbanibulin ointments, which are being developed for the treatment of actinic keratosis, certain skin cancers, and psoriasis. The company's pipeline further includes several advanced cell therapy programs. KUR-501, an autologous product, is in a Phase I clinical trial addressing relapsed-refractory (R/R) high-risk neuroblastoma in pediatric patients. KUR-502, an allogeneic product, is also in a Phase I clinical trial, targeting R/R CD19 positive malignancies in adults, such as B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. For advanced hepatocellular carcinomas, Athenex is progressing KUR-503, an allogeneic product in preclinical development. Moreover, TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy, is undergoing a Phase 1 clinical trial for solid tumors. Beyond these, Athenex is developing novel dual absorption enhancers designed to obstruct the P-gp transporter and cytochrome p450 3A enzymes within the gastrointestinal tract. It also possesses a robust portfolio of T cell receptors engineered to identify hotspot mutations in genes like p53, KRAS, and EGFR, applicable across multiple tumor types. Tracing its origins, the company was established in 2003 and was initially known as Kinex Pharmaceuticals LLC before officially adopting the name Athenex, Inc. in August 2015. Its corporate headquarters are situated in Buffalo, New York.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ATNX position with:
Real after-tax yield depends on where you live and how you hold ATNX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 984.74% | 981.94% | $98,474 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 837.03% | 834.23% | $83,703 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 787.79% | 784.99% | $78,779 / yr |
| 🇬🇧 UK ISA | 0% | 984.74% | 981.94% | $98,474 / yr |
| 🇬🇧 UK Taxable | 8.75% | 898.58% | 895.78% | $89,858 / yr |
| 🇨🇦 TFSA | 0% | 984.74% | 981.94% | $98,474 / yr |
| 🇨🇦 CA Taxable | 25% | 738.56% | 735.76% | $73,856 / yr |
| 🇦🇺 Super (pension) | 15% | 837.03% | 834.23% | $83,703 / yr |
| 🇦🇺 AU Taxable | 30% | 689.32% | 686.52% | $68,932 / yr |
| 🇩🇪 DE Taxable | 26.375% | 725.01% | 722.21% | $72,501 / yr |
| 🇫🇷 FR Taxable | 30% | 689.32% | 686.52% | $68,932 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ATNX pays quarterly — 4 times per year. Next ex-div: TBD.
How ATNX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ATNX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2023-05-05 | 8,382 | $1.36 | $11.4K | ||
| A-Award | 2023-05-05 | 3,603 | $1.36 | $4.9K | ||
| A-Award | 2023-05-05 | 368 | $1.36 | $500.00 | ||
| A-Award | 2023-04-21 | 6,513 | $1.30 | $8.5K | ||
| A-Award | 2023-04-21 | 6,513 | $1.30 | $8.5K | ||
| A-Award | 2023-04-21 | 8,813 | $1.30 | $11.5K | ||
| A-Award | 2023-04-21 | 2,300 | $1.30 | $3.0K | ||
| A-Award | 2023-04-21 | 8,736 | $1.30 | $11.4K | ||
| A-Award | 2023-04-21 | 3,755 | $1.30 | $4.9K | ||
| A-Award | 2023-04-21 | 5,747 | $1.30 | $7.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ATNX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Athenex, Inc. (ATNX) is currently trading at $0.20, trading near its 52-week low. The current dividend yield is 984.74% based on an annual payout of $2.00 per share.
Athenex, Inc. (ATNX) is a healthcare stock currently trading at $0.20 with a dividend yield of 984.74%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever